Sovaldi (sofosbuvir) / Gilead - LARVOL DELTA

Navigating Therapeutic Frontiers: A Meta-review and Meta-analysis of COVID-19 Treatment Options. (PubMed, J Res Pharm Pract) - "285 reviews with 152 meta-analyses were included, The analysis of systematic reviews contents indicated that most reviewed drugs were as follows: chroquine/hydroxychloroquine (n = 48), tocilizumab (n = 39), remdesivir (n = 25), corticosteroids (n = 25), JAK inhibitors (n = 12), colchicine (n = 11), ivermectin (n = 8), anakinra (n = 7), favipravir (n = 7), lopinavir/ritonavir (n = 6), ACEI/ARB (n = 6), azithromycin (n = 4), sofosbuvir (n = 4), and Vitamin D (n = 4)...lower requirement for mechanical ventilation and intensive care unit admission and a shorter hospital length of stay was observed with the tocilizumab, JAKIs, anakinra, corticosteroids and sofosbuvir Only one third of the included reviews had 70% quality based on the AMSTAR scale assessment. The results of this study have the potential to be a useful tool for the translation of health evidence and for designing the decision support systems for evidence synthesis."

Journal • Retrospective data • Review • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Oral MDL-001 a Universal Direct Acting Antiviral for Chronic Hepatitis: In Vivo Equivalence to Sofosbuvir, Single-Agent Activity Against HCV/HBV and HDV/HBV Coinfections. (IDWeek 2026) - No abstract available

Preclinical • Hepatitis B • Hepatitis C • Infectious Disease

RNA synthesis and substrate analogue inhibition in the CCHFV polymerase. (PubMed, Nature) - "Nucleotide analogues with ribose-2' modifications identical to the hepatitis C drug sofosbuvir are found to specifically and efficiently inhibit CCHFV RdRP through an immediate chain termination mechanism. Using a sofosbuvir-hepatitis C virus RdRP system as the reference, the potency of these nucleotide analogues is further demonstrated in competition assays in the presence of corresponding nucleoside triphosphates."

Journal • Hepatitis C • Infectious Disease • Inflammation

Novel Mechanisms of SARS-CoV-2 Drug Resistance and Rational Design of Anti-Resistant Antivirals. (PubMed, Molecules) - "Four recent studies have revealed two key resistance mechanisms: (1) Mutations in the main protease (Mpro)-including E166V, E166A, and S144-series variants-disrupt drug binding or active-site conformation, reducing nirmatrelvir efficacy. (2) The proofreading exoribonuclease (ExoN) removes incorporated nucleoside analogues (e.g., bemnifosbuvir, sofosbuvir), conferring resistance. Guided by structural and pharmacological insights, three effective countermeasures have been established: structure-based optimization of Mpro inhibitors, rational design of ExoN-evading nucleoside analogues, and synergistic combination therapies. These advances provide a solid framework for developing next-generation antivirals to combat emerging resistant SARS-CoV-2 variants."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

STRIVE-4: Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (clinicaltrials.gov) - P4 | N=30 | Recruiting | Sponsor: Kirby Institute | Trial completion date: Feb 2026 ➔ Jul 2029 | Trial primary completion date: Feb 2026 ➔ Jul 2029

Trial completion date • Trial primary completion date • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Mitigating intellectual property barriers to HIV and comorbidities treatment in Eurasian Patent Organization countries: programme results and policy implications (AIDS 2026) - "The drugs included tenofovir/emtricitabine (Armenia, Russia), rilpivirine (Russia), long-acting rilpivirine, islatravir, lenacapavir (EAPO); sofosbuvir (Russia); molnupiravir (EAPO, Russia), nirmatrelvir (EAPO); pretomanid in bedaquiline/pretomanid/linezolid regimen, pretomanid granulate, pretomanid amorphous form (EAPO), bedaquiline (Belarus, Kazakhstan, Kyrgyzstan). EECA communities developed expertise on patent challenges, successfully opposed patents, and revealed and addressed systemic barriers to CSO engagement in access-related IP work. The programme has potential for expansion, as demonstrated by a CBO opposition in Uzbekistan in December 2025 (delamanid). Results from the structural barrier analysis call for legal reform to enhance community involvement in mitigating IP barriers and improving access to medicines."

Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • Tuberculosis

Chiral-Modified Nucleoside Analogues: From Bioactivity to Therapeutic Applications. (PubMed, Pharmaceuticals (Basel)) - "During recent extensive structure-activity studies, several drugs and their prototypes have been proposed for the treatment of viral infections: the 2'C-fluoromethyl derivative of sofosbuvir (anti-SARS-CoV, preclinical), VV-261 (SFTSV, phase I clinical), balapiravir (dengue, phase I clinical), mericitabine (approved drug for HCV), and lumicitabine (approved drug for RSV and HMPV). Modern literature data within the scope of the present review suggest that direct modification of nucleosides with various chiral functionalities can be considered as an approach to increase their efficacy, specificity and selectivity."

Journal • Review • Dengue Fever • Infectious Disease • Oncology • Respiratory Syncytial Virus Infections

From precedent to practice: proven policy options for countries seeking affordable lenacapavir (AIDS 2026) - "From early antiretroviral therapy scale-up to more recent medicines such as dolutegravir and sofosbuvir for HCV, countries excluded from voluntary licensing or preferential pricing have relied on coordinated policy and legal action to secure affordable access. Lenacapavir presents a clear policy choice for middle-income countries: accept delayed or unaffordable access, or act based on proven precedent. Past experience shows that voluntary mechanisms alone are insufficient. Coordinated government and civil society action, using established policy tools, offers a viable and lawful pathway to ensure equitable access to lenacapavir and prevent a new generation of HIV innovations from remaining out of reach."

Human Immunodeficiency Virus • Infectious Disease

Know the market, change the game: using market intelligence for access (AIDS 2026) - "Subsequent MI identified rising prices and limited competition, and price benchmarking; advocacy with the Ministry of Health (MoH) led to PAHO Strategic Fund procurement and annual savings of $14.5 million (tenofovir/emtricitabine) and $0.98 million (sofosbuvir) in 2021. In Kazakhstan, MI revealed prices of up to $1,842 per person per year, for dolutegravir (DTG), consuming a large budget share, while reaching few people... MI identifies opportunities to reducing medicine prices through procurement reforms and use of TRIPS flexibilities; fosters dialogue between CS/CBOs, MoH, procurement agencies, and local manufacturers; supports long-term collaboration and strengthens national autonomy in medicines procurement. Consortium-based work enables countries to share tools and lessons learned, increasing impact. Next steps include expanding regular national reporting and systematizing global MI reports to support comparative analysis and coordinated advocacy."

Cervical Cancer • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Respiratory Diseases • Solid Tumor • Tuberculosis

Development, Characterization, and Preclinical Evaluation of Curcumin-Loaded Solid Lipid Nanoparticles for Enhanced Antiviral Delivery Against Zika Virus Infection. (PubMed, J Drug Target) - "Histopathological analysis in a lethal AG129 mouse model showed that CUR-SLN6 treatment provided marked protection against ZIKV-induced neuronal necrosis and inflammation, with efficacy comparable to Sofosbuvir...Stability studies confirmed the formulation's robustness. This study is the first to demonstrate that SLN-based delivery of curcumin not only enhances its bioavailability and brain targeting but also provides neuroprotective efficacy against ZIKV infection comparable to a direct-acting antiviral, highlighting its clinical potential as an oral neurotherapeutic agent."

Journal • Preclinical • CNS Disorders • Infectious Disease • Inflammation

Efficacy of 12 Weeks Versus 24 Weeks Treatment of Directly Acting Antiviral Therapy in Patients With Hepatitis C Related Chronic Liver Disease (clinicaltrials.gov) - P=N/A | N=192 | Completed | Sponsor: Indus Hospital and Health Network

New trial • Hepatitis C • Hepatology • Infectious Disease • Inflammation • AFP

Use of De Novo Belatacept (Bela) in Kidney Transplant Recipients (KTRs) Who Receive HCV NAT (+) Organs (ATC 2026) - "MMF was dosed by weight, and prednisone was maintained at 5mg. Basiliximab induction was given as a single dose prior to July 2024 and discontinued thereafter...All patients were prescribed sofosbuvir/velpatasavir and SVR12 was achieved... Bela appears to be a safe and effective IS agent when used in KTRs receiving HCV NAT(+) organs. None of the differences identified were statistically significant. Wide confidence intervals suggest results should be interpreted cautiously, especially given the small sample size and relatively few events."

Clinical • Hepatitis C • Infectious Disease • Transplant Rejection • Transplantation

Time to viral load suppression with 8-week versus 12-week ravidasvir/sofosbuvir regimens among chronic hepatitis C patients in Malaysia: a non-inferiority, randomized clinical trial. (PubMed, BMC Infect Dis) - P2/3 | "Both 8-week and 12-week RDV/SOF regimens achieved rapid viral suppression, with comparable median times to viral suppression. The 8-week regimen was associated with a higher likelihood of earlier suppression; however, given the modest statistical power, this finding should be interpreted with caution. The results suggest potential as an effective alternative in Genotype 1 patients. However, given the significant treatment-by-genotype interaction, the magnitude of benefit with the shorter regimen in the predominant Genotype 3 population warrants further investigation before broad programmatic recommendations can be made."

Clinical • Head-to-Head • Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

A Database-Derived Global Overview of HCV Resistance-Associated Substitutions: Characterizing Genotypic, Regional, and Temporal Heterogeneity. (PubMed, Int J Mol Sci) - "Importantly, RASs against pan-genotypic NS3 protease inhibitors (glecaprevir and voxilaprevir) were rare (generally <1% across genotypes)...The NS5B nucleotide analogue sofosbuvir retained a high genetic barrier, with the canonical S282T substitution detected only sporadically (2.1% of genotype 4 sequences)...Temporal analyses revealed an increase in NS3 and NS5A RASs following the introduction of first-generation DAAs, with NS5A substitutions persisting into the current interferon-free era, whereas NS5B resistance remained consistently rare across all treatment periods. Together, these findings provide a global, population-level overview of resistance-associated HCV diversity and reinforce the durability of high-barrier regimens while highlighting persistent genotype-specific vulnerabilities with implications for antiviral resistance surveillance and HCV elimination efforts."

Heterogeneity • Journal • Hepatitis C • Infectious Disease • Inflammation

Replication assessment of chimeric HEV-3 subtypes demonstrate enhanced replication fitness of HEV-3f isolates (EASL 2026) - "We evaluated replication kinetics and antiviral responses to ribavirin and sofosbuvir. Our findings highlight the genomic flexibility of HEV-3, which allows for efficient replication of diverse chimeric constructs. This model provides a robust platform for assessing intra-genotypic variability in antiviral responses and advances our mechanistic understanding of replication fitness. Such insights are critical for optimising treatment strategies and understanding the burden of disease in HEV-infected patients."

Hepatology • Infectious Disease • Inflammation

Discovery and preclinical profiles of a first-in-class potent hepatitis E virus inhibitor AT-587 (EASL 2026) - "Currently, there are no HEV-specific antivirals, and therapeutic options for HEV infection are limited to off-label use of ribavirin (RBV) and pegylated- interferon-α...AT-587 is >50-fold more potent against HEV than known nucleos(t)ide inhibitors such as sofosbuvir and RBV... AT-587, a nucleotide prodrug, has been identified as a highly potent pan-genotypic inhibitor of HEV and nominated as an IND candidate for the treatment of life-threatening HEV infection."

Preclinical • Chikungunya • Hepatology • Infectious Disease • Inflammation • Liver Failure

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (clinicaltrials.gov) - P=N/A | N=21 | Terminated | Sponsor: Kirby Institute | Once recruitment recommenced it remained slow. Removal of Sofosbuvir from the PBS November 2020 impacted recruitment into Cohort B. Study closed early on 15-Sep-26.

Enrollment change • Trial completion date • Trial termination • Fibrosis • Hepatitis C • Infectious Disease • Inflammation • Liver Cirrhosis • CD4

MDL-001, an oral direct-acting Thumb-1 polymerase inhibitor, demonstrates efficacy against HCV/HBV co-infection in vitro, and achieves HCV and HBV preclinical proof-of-concept, including equivalence to sofosbuvir (EASL 2026) - "MDL-001 directly targets the Thumb-1 cryptic allosteric site that is present across RNA-dependent viral polymerases, delivering dual preclinical efficacy against HCV and HBV, as well as activity against HCV/HBV co-infection, with a safety and pharmacokinetic profile consistent with oral dosing. These data support completion of IND-enabling studies and clinical evaluation in chronic hepatitis B and C, including co- infected cohorts."

Preclinical • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Integrative proteome-wide structural analysis and high-throughput docking identify broad-spectrum antiviral scaffolds against Zika, Yellow Fever, West Nile, Saint Louis encephalitis, and Usutu viruses. (PubMed, Front Cell Infect Microbiol) - "Among the 40 top-ranked scaffolds, several flavonoids exhibited dual-site binding to the NS5 polymerase and E glycoprotein across at least four viruses, while ribavirin and sofosbuvir engaged conserved catalytic motifs in NS3/NS5, highlighting opportunities for combination strategies. Lead compounds such as myricetin (Estimated Kd ≈ 1.9 µM), temoporfin (Estimated Kd ≈ 1.2 nM), and aurintricarboxylic acid (Estimated Kd ≈ 1.9 µM) demonstrated favorable multitarget profiles. This integrative framework prioritizes robust candidates for experimental validation and optimization of panflaviviral therapeutics."

Journal • CNS Disorders • Infectious Disease

A Multicenter, Open-Label, Randomized, Non-Inferiority Trial of 8 Versus 12 Weeks of Sofosbuvir/Ravidasvir Treatment in Non-Cirrhotic Patients with Chronic Hepatitis C Virus Infection (EASE Trial). (PubMed, Int J Infect Dis) - P2/3 | "An 8-week sofosbuvir/ravidasvir regimen achieved SVR12 comparable to 12 weeks in non-cirrhotic adults with chronic HCV infection and was well tolerated. Further pragmatic and cost-effectiveness studies are needed to inform large-scale implementation."

Head-to-Head • Journal • Fibrosis • Hepatitis C • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Comparative effectiveness of antiviral therapies in chronic hepatitis B and C management. (PubMed, Bioinformation) - "Hence, this study compares four antiviral regimens across 480 patients (4 groups of 120 each): tenofovir or entecavir for HBV and sofosbuvir-based or glecaprevir/pibrentasvir combinations for HCV over 48 weeks. Both drug classes demonstrated high efficacy in halting viral replication and minimizing progression to chronic liver damage. These results advance therapeutic knowledge by identifying glecaprevir/pibrentasvir as a marginally superior HCV regimen and reinforcing evidence-based antiviral selection for durable viral suppression."

HEOR • Journal • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Efficacy and Safety of 12-Week Coblopasvir/Sofosbuvir Regimen for Hepatitis C in Northwest China: A Multi-Center Prospective Study. (PubMed, J Med Virol) - "The COB/SOF combination achieved high SVR12 rates (> 99%) across diverse HCV genotypes in Northwest China, including cirrhotic patients, with concurrent liver function recovery and stable renal parameters. These real-world data support its first-line application in resource-limited regions."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Renal Disease

Comparing Care Settings for Sofosbuvir/ Ravidasvir Delivery in Hepatitis C: Nested Cohort Findings from the EASE Trial (APASL 2026) - No abstract available

Hepatitis C • Hepatology • Infectious Disease • Inflammation

Time to Viral Load Suppression with 8- versus 12-Week Ravidasvir/Sofosbuvir Regimens among Chronic Hepatitis C Patients in Malaysia (APASL 2026) - No abstract available

Clinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Molnupiravir is effective against hepatitis E virus infection in an animal model. (PubMed, Hepatol Commun) - "Molnupiravir limits HEV infection in cell culture and animal models. Molnupiravir could be an alternative for ribavirin-refractory chronic hepatitis E."

Journal • Preclinical • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • Transplantation